Skip to main content

Table 1 Patient characteristics

From: TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience

Characteristics

N (%)/median (IQRa)

Gender

 Male

112(91.1%)

 Female

11(8.9%)

Age

58(47-64)

 < 60

69(56.1%)

 ≥60

54(43.1%)

Aetiology of liver disease

 Hepatitis B

117(95.2%)

 Hepatitis C

3(2.4%)

 Alcoholic cirrhosis

3(2.4%)

BCLC classificationa

 A

14(11.4%)

 B

27(22.0%)

 C

71(57.7%)

 D

11(8.9%)

PVTTa

 No

43(35.0%)

 Yes

80(65.0%)

Number of tumors

 Single

42(34.1%)

 Multiple

81(65.9%)

MELDa

14.50(13.34-15.75)

 <15

76(61.8%)

 ≥15

47(38.2%)

Symptomatic portal hypertension

 Refractory ascites

51(41.5%)

 Variceal bleeding

49(39.8%)

 Both

23(18.7%)

 Refractory diarrhea

5(4.1%)

Laboratory tests

 Platelets [109/L]

88(65-125)

 INRa

1.26(1.15-1.43)

 AST [U/L] a

46.3(34.0-65.0)

 ALT [U/L] a

37.6(25.4-52.1)

 Albumin [g/dL]

33.2(30.2-36.8)

 Creatinine [mg/dL]

72(62.2-86.5)

 Bilirubin [mg/dL]

29.8(19.2-41.0)

 AFP [ng/mL] a

16.2(4.81-463.78)

 <100

42(34.1%)

 ≥100

81(65.9%)

  1. PVTT Portal vein tumor thrombosis, MELD Model of end stage liver disease, INR International normalised ratio, AST Aspartate aminotransferase, ALT Alanine transaminase, AFP Alpha fetoprotein, CI Confidence interval, IQR Interquartile range
  2. aBarcelona Clinic Liver Cancer